Comirnaty (Original/ Omicron XBB.1.5): Updated mRNA COVID-19 vaccine in focus for US adults

Pfizer’s Comirnaty (Original/Omicron XBB.1.5) mRNA COVID-19 vaccine targets currently circulating Omicron lineages and remains widely available for adults and adolescents in the US, with updated guidance on dosing, eligibility and access through major pharmacies and clinics.

Responsible: ad hoc news Classics & Long-sellers Desk. Reviewed prior to publication on June 14, 2026 at 5:40:28 PM ET. Details in the imprint.

Comirnaty (Original/Omicron XBB.1.5), the latest formulation of Pfizer’s long-running mRNA COVID-19 vaccine, remains a central vaccination option for US adults and adolescents as health authorities continue to emphasize protection against currently circulating Omicron-lineage variants. The product, co-developed with BioNTech, is authorized in the United States for individuals 12 years of age and older, with specific dosing recommendations depending on prior vaccination status and risk factors. For US consumers, Comirnaty is available at large pharmacy chains, doctor’s offices and public health clinics, with costs for many people covered by private insurance or government programs such as the CDC Bridge Access Program for the uninsured. As a classic product that has been updated multiple times since its first emergency authorization in 2020, Comirnaty now occupies a role similar to seasonal flu vaccines in the preventive care landscape.

What Comirnaty (Original/Omicron XBB.1.5) offers today

The current Comirnaty (Original/Omicron XBB.1.5) formulation is designed to target the Omicron XBB.1.5 strain and closely related variants, following recommendations from the US Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) to align COVID-19 vaccines with the most prevalent strains. According to FDA and CDC information, this monovalent XBB.1.5-adapted mRNA vaccine aims to broaden protection against severe disease, hospitalization and death, even as specific sublineages evolve. The vaccine uses the same mRNA platform and lipid nanoparticle technology as earlier versions, encoding the spike protein of the targeted variant so the immune system can recognize and respond to the virus if exposed. Clinical and real-world data cited by public health agencies indicate that updated mRNA vaccines restore waning protection, particularly in older adults and individuals with underlying health conditions. While no vaccine offers 100 percent protection, regulators point to a meaningful reduction in severe outcomes among vaccinated populations compared with those who remain unvaccinated.

In the United States, Comirnaty (Original/Omicron XBB.1.5) is typically administered as a single dose for most people who have previously received any COVID-19 vaccine, with additional doses recommended for certain immunocompromised individuals based on CDC guidance. Adults and adolescents 12 years of age and older who have never received a COVID-19 vaccine may receive a primary series defined by current CDC schedules, which can include one or more doses depending on age and health status. The vaccine is delivered as an intramuscular injection, usually in the upper arm, and is supplied to providers as a ready-to-use formulation that does not require dilution, simplifying handling compared with the earliest versions introduced in 2020. Commonly reported side effects include pain at the injection site, fatigue, headache, muscle pain and chills, which are generally mild to moderate and resolve within a few days. Rare risks such as myocarditis and pericarditis, particularly in younger males, continue to be monitored through safety surveillance systems in the US and internationally. For most eligible individuals, public health authorities judge that the benefits of vaccination in preventing severe COVID-19 outweigh these rare risks.

From an access perspective, Comirnaty (Original/Omicron XBB.1.5) is broadly distributed across the US through pharmacy chains, supermarket pharmacies, independent pharmacies and health systems. The CDC Bridge Access Program provides COVID-19 vaccines at no cost to uninsured and underinsured adults through participating providers, helping maintain access even after the end of the broader federal government purchase program. For those with private insurance, the Affordable Care Act’s preventive services requirements generally mean that in-network COVID-19 vaccines are covered with no out-of-pocket cost, though consumers may want to confirm details with their health plans. Children and adolescents may also receive COVID-19 vaccines through the federal Vaccines for Children (VFC) program when eligible, though dosing and product options vary by age group and are specified in CDC schedules. Pharmacies often allow online scheduling and walk-in appointments, and many retailers promote seasonal COVID-19 vaccination alongside influenza and RSV options where appropriate. For US consumers trying to locate the product, tools such as the CDC’s vaccine finder and pharmacy locator services list nearby Comirnaty providers and appointment availability.

Like earlier versions, the Comirnaty (Original/Omicron XBB.1.5) formulation has specific storage and handling requirements that providers must follow to maintain potency. Pfizer’s professional materials describe storage in ultracold or freezer conditions for longer-term holding, with defined time windows for refrigerator storage before administration. The ready-to-use presentation reduces preparation steps for vaccinators, decreasing the potential for dosing errors and speeding throughput during busy vaccination periods. Multi-dose vials allow multiple doses to be drawn from a single container, which is efficient in high-volume settings but requires careful adherence to discard times after puncture. For patients, these logistical details are largely invisible, but they influence how pharmacies schedule appointments, manage inventory and minimize waste. The repeated refreshes of Comirnaty’s formulation also require providers to keep track of expiration dates and product identifiers to ensure that only the latest, current-season vaccine is offered.

On the scientific side, the use of the mRNA platform allows Pfizer and BioNTech to update Comirnaty relatively quickly in response to new variants, subject to regulatory review and public health recommendations. This flexibility is one reason regulators have drawn analogies between COVID-19 vaccines and seasonal influenza vaccines, where strain composition is reviewed annually. According to public communications from agencies and companies, the goal is to maintain a vaccine that matches or closely approximates circulating variants, improving the likelihood of strong immune responses. Real-world effectiveness analyses from previous Omicron-adapted vaccines have shown that updated doses provide additional protection on top of prior vaccination or infection, especially in older age groups. While the degree of protection can decline over time as immunity wanes and the virus changes, booster doses with updated formulations help restore protection to higher levels, particularly against severe outcomes. For consumers, this has translated into recommendations to receive an updated dose if it has been several months since the last COVID-19 vaccine or infection, depending on age and risk profile.

From a product-portfolio perspective, Comirnaty remains one of Pfizer’s most visible branded medicines, even though sales have declined from peak pandemic levels. Company disclosures show that COVID-19 products, including Comirnaty and the oral antiviral Paxlovid, contributed significantly to revenue in 2021 and 2022, while more recent guidance reflects a transition to a more typical seasonal market. As the market matures, Pfizer’s strategy has included updating the vaccine, expanding manufacturing capacity in key regions and working with governments and private payers to define post-emergency purchasing arrangements. The prominence of Comirnaty has also influenced public perception of Pfizer, putting the vaccine’s safety profile, pricing, access and communication under continuous scrutiny from regulators, health professionals and the public. For consumers and private investors following the brand, the product’s evolution illustrates how a classic vaccine can shift from an emergency-response tool to a recurring seasonal healthcare product with ongoing updates.

Comirnaty (Original/Omicron XBB.1.5) therefore continues to play a notable role in Pfizer’s vaccine business as a mature but regularly refreshed product aligned with evolving Omicron-lineage strains and seasonal vaccination campaigns. Shares of Pfizer Inc. (US7170811035, ticker PFE) traded at $26.19 on the New York Stock Exchange on June 13, 2026.

Comirnaty (Original/Omicron XBB.1.5) at a glance

• Product: Comirnaty (Original/Omicron XBB.1.5)
• Manufacturer: Pfizer Inc.
• Category: Classic long-seller vaccine
• Launch date: Updated XBB.1.5 formulation introduced for the 2023-2024 season in the US
• MSRP / Price: Commercial list prices vary; many US adults pay $0 out of pocket through insurance or federal programs (as of 2025)
• Availability: Widely available in the US at major pharmacy chains, clinics and physician offices; appointments and walk-ins supported in many locations
• Target audience: Individuals 12 years and older, especially older adults and those with underlying conditions, following CDC and FDA recommendations
• Key feature / USP: mRNA-based COVID-19 vaccine updated to target Omicron XBB.1.5-lineage variants while building on years of safety and effectiveness data

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.